A new immunotherapy treatment that has recently been administered to a patient suffering from mesothelioma has researchers and scientists optimistic that if results are positive, this treatment could be more effective than Keytruda, the immunotherapy treatment that has had major success in non-small cell lung cancer The name of the treatment is CA-170, and while
Archive for the 'Keytruda' Category
As the success of immunotherapy treatments in improving survival and symptom management for cancer patients have started to become known, those suffering from cancer such as mesothelioma and lung cancer may now be given options in terms of the best course of treatment. Immunotherapy works with the body’s own natural defense system by strengthening and
Immunotherapy is revolutionizing the health care industry by adding extra years of life to people with lung cancer. A few years ago it was rare for patients with an advanced stage of this disease to live past two years but today it has become more common to do so. Immunotherapy treatment works by boosting immune
Survival rates for diffuse mesothelioma are notoriously low with the median survival ranging between 12 to 22 months. A contributing factor to treatment being ineffective is that the disease if often in the advanced stages by the time it is noticed and diagnosed. Early detection may be a key factor in fighting this illness effectively,
A new immunotherapy developed by Targovax has recently passed Phase I clinical trials and is set to begin Phase II evaluation of this new treatment that may help those suffering from mesothelioma. ONCOS-102 was used in separate Phase I clinical trials; one in combination with chemotherapy, and one with immunotherapy. Cisplatin and pemetrexed are two
Last update: April 01, 2019. 03:30:08 pm.